Liraglutide
About
About Liraglutide
Liraglutide is a once-daily GLP-1 receptor agonist marketed as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first GLP-1 agents to demonstrate meaningful weight loss in clinical trials, producing 5–8% body weight reduction on average. Though largely superseded by weekly agents, it remains a clinically validated option. Compounded liraglutide is available through select pharmacies.
Science
Mechanism of Action
Mimics endogenous GLP-1 by binding to GLP-1 receptors in the pancreas, hypothalamus, and gut, increasing insulin secretion, slowing gastric emptying, and reducing appetite. Its 13-hour half-life requires daily dosing.
Dosing
Typical Protocol
0.6 mg subcutaneous once daily for 1 week, titrating weekly to a maximum of 3.0 mg/day.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound has completed clinical trials and received formal FDA approval for one or more indications. It can be legally prescribed by licensed physicians, filled at any licensed pharmacy, and may be covered by insurance. Off-label use by physicians is also legal. This is the highest level of regulatory clearance available in the US.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Find a Verified Provider
See which Vial-verified providers offer Liraglutide — with trust scores, legal credentials, and pricing transparency.